StockData
IceCure Medical Ltd. logo

IceCure Medical Ltd. (ICCM) company profile

ICCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 17, 2026Score 2/30
$0.83+0.07 (+9.21%)

Close on Nov 17, 2026Market cap $2.84MP/E 0.1Yield –

About IceCure Medical

Surgical & Medical Instruments & Apparatus, SIC 3841

IceCure Medical Ltd. is an Israeli medical device company that researches, develops, and commercializes liquid-nitrogen-based cryoablation systems to destroy benign and malignant tumors through freezing. Its proprietary technology provides a minimally invasive alternative to surgery for tumors in the breast, lungs, kidneys, and bones. The company's lead commercial product is the ProSense system alongside its single-use disposable CryoProbes, while its pipeline includes next-generation systems such as the single-probe XSense and multi-probe MSense platforms. IceCure primarily markets its cryoablation products to healthcare providers, physicians, and hospitals treating low-risk breast cancer and other tumor indications.

The company's cryoablation systems hold regulatory approvals for various clinical indications in 27 countries, including the United States, several European nations, China, India, and Brazil. IceCure maintains its corporate headquarters and principal executive offices in Caesarea, Israel, and operates wholly owned subsidiaries in the United States and Hong Kong.

Summary of the business section of IceCure Medical's latest annual report, written by StockData.

Company profile

Company

Legal name
IceCure Medical Ltd.
Founded
2006
Headquarters
Caesarea, Israel
Address
7 Ha'Eshel St., Pob 3163 38900
Phone
972-4-6230333
Employees
67, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
L3
Fiscal year ends
December 31
Auditor
Brightman Almagor Zohar & Co., Tel Aviv, Israel

Stock & identifiers

Ticker
ICCM
Exchange
Nasdaq
IPO date
Aug 26, 2021
Shares outstanding
73M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Emerging growth company
Stock splits
1-for-30 reverse, Jun 4, 2026
SEC CIK
1584371
CUSIP
M53071136
FIGI
BBG005K17W05
Share class FIGI
BBG001V04FF8
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Eyal ShamirChief Executive Officer, Director431,281
Shad GoodVP, Sales for North America136,698
Shay LevavChief Operating Officer146,303
Tlalit Bussi Tel-TzureVP, BD & Global Marketing106,518
Meir PelegChief Financial Officer194,816
Merav Nir DotanVP, Human Resources76,168
Naum MuchnikVP, R&D & Engineering118,621
Ronen TsimermanChief Financial Officer177,949
Ron MayronDirector176,464
David SaltonDirector–
Vincent Chun Hung ChanDirector–
Sharon LevitaDirector–
Yonatan MalcaDirector–
Yang HuangDirector111,468

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 10, 2021
Offer price
$3.45
Exchange
Nasdaq
Lock-up ends (est.)
Jun 8, 2022

“Per Ordinary Share Per Pre-Funded Warrant Total Public offering price $ 3.45 $ 3.449 $ 14,998,969.15 Underwriting discounts and commissions (1) $ 0.1104 $ 0.1035 $ 472,729 Proceeds to us (before expenses) $ 3.34 $ 3.35 $ 14,526,240.15 (1) The underwriters will receive an underwriting discount equal to 7.0% of the gross proceeds in this offering (”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“we had 67 full-time employees and two part time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 23, 2021ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?